Your search for major depressive disorder returned 152 results

Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.

AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.

Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.

The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.

For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.

Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.

Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.

Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.

The researchers of this study explored the impact of a blended approach (bCBT) that included both face-to-face CBT and iCBT on patients with major depressive disorder and insomnia.

Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.

The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.

Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.

Data about grade point averages during transitions from early, intermediate, and upper compulsory education and to vocational or university education were sourced from population-based registers in Sweden.

There was insufficient evidence to recommend screening in children aged 11 and younger.

Investigators sourced data for this study from the Stockholm Major Depressive Disorder Cohort. Between 2010 and 2018, all patients in the Stockholm region who met the criteria for MDD were enrolled in the cohort.

Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.

Convergent abnormalities were observed in secondary analyses across portions of the amygdala, hippocampus, subgenual cingulate cortex, and putamen.

This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.

The US Preventive Services Task Force (USPSTF) recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years, and recommends anxiety screening for children aged 8 to 18 years.

Sixty percent of patients responded to treatment.

The approval was based on the ASPIRE I and II trials that compared the efficacy and safety of esketamine, an N-methyl-D-aspartate receptor antagonist, to placebo in 449 adults with moderate to severe MDD who had active suicidal ideation and intent.

Researchers evaluated the effect of traumatic events, including PTSD, on treatment adherence and outcomes in eating disorders.

For patients with MDD, the change in scores for depression at six weeks does not differ significantly with psilocybin or psilocybin plus escitalopram.

Patients with psychotic depression who experienced an illness relapse while receiving placebo also had a decline in cortical thickness, emphasizing the essential role antipsychotics play in treating disorders where psychosis is present.

Researchers explored the neurobiology related to reward-based reinforcement learning and psychomotor retardation in patients in remission from MDD.

This was a study protocol for a phase II pilot feasibility study that will assess the feasibility of ketamine for depression in patients with advanced life-limiting illnesses.

Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.

Most older adults with preexisting MDD showed resilience in the first two months of the COVID-19 pandemic, but they express concerns about the future.

The study provides strong evidence for the utility of resting-state fMRI measures in predicting the development of attentional or mood disorders in children.

The drug was found to work quickly in patients with clinical major depression.